body mass index (BMI)

身体质量指数 (BMI)
  • 文章类型: Journal Article
    本研究的目的是独立评估骨骼肌指数(SMI)和体重指数(BMI)作为肾细胞癌(RCC)的预后决定因素,并探讨其与手术结果的相关性。
    使用丹麦新西兰大学医院肾癌数据库的数据,对2010年8月至2018年7月诊断的524例肾癌患者进行了一项回顾性队列研究。患者信息从电子患者记录和国家癌症登记处提取,并包含人口统计数据。临床因素,肿瘤特征和手术细节。通过CoreSlicer软件从单个第三腰椎(L3)轴向计算机断层扫描(CT)图像中计算出SMI,并使用性别特异性阈值将其分类为高。主要结果集中在90天内的并发症以及生存结果。以及它们与SMI和BMI的关系。多变量分析评估了SMI在RCC中的独立预后意义。
    在524名患者中,18.5%出现并发症,与高SMI显着相关(p=0.018),并发症风险高72%。高SMI患者的并发症发生率为22.7%,而低SMI组为14.5%。高SMI也与延长生存期(110.95vs.94.87个月;p=0.001),而BMI无显著生存差异(p=0.326)。多变量分析(n=522)显示高SMI与提高生存率相关(风险比[HR]=0.738;95%CI,0.548-0.994;p=0.046)。晚期T期显著影响死亡率(T2:HR=2.057;T3:HR=4.361;p<0.001),年龄每增加一年,死亡风险增加4.3%(HR=1.043;p<0.001)。
    较高的SMI会增加术后并发症的风险,然而,它显著提高了总生存率。不同的BMI类别缺乏RCC预后意义。RCC发病率的增加要求使用CT扫描来评估SMI并帮助可能从术前干预中受益的患者制定治疗计划。
    UNASSIGNED: The objective of this study is to independently assess skeletal muscle index (SMI) and body mass index (BMI) as prognostic determinants for renal cell carcinoma (RCC) and investigate their correlation with surgical outcomes.
    UNASSIGNED: A retrospective cohort study of 524 RCC patients diagnosed between August 2010 and July 2018 was conducted using data from the Zealand University Hospital Renal Cancer Database in Denmark. Patient information was extracted from electronic patient records and the National Cancer Registry and encompassed demographics, clinical factors, tumour characteristics and surgical details. SMI was calculated from a single third lumbar vertebra (L3) axial computed tomography (CT) image via CoreSlicer software and classified into high using gender-specific thresholds. Primary outcomes focused on complications within 90 days as well as survival outcomes, and their relation with both SMI and BMI. Multivariable analysis assessed SMI\'s independent prognostic significance in RCC.
    UNASSIGNED: Among 524 patients, 18.5% experienced complications, with high SMI correlating significantly (p = 0.018) with a 72% higher complication risk. High SMI patients had a 22.7% complication rate compared to 14.5% in the low SMI group. High SMI was also linked to prolonged survival (110.95 vs. 94.87 months; p = 0.001), whereas BMI showed no significant survival differences (p = 0.326). Multivariable analysis (n = 522) revealed high SMI associated with improved survival (hazard ratio [HR] = 0.738; 95% CI, 0.548-0.994; p = 0.046). Advanced T-stage significantly impacted mortality (T2: HR = 2.057; T3: HR = 4.361; p < 0.001), and each additional year of age raised mortality risk by 4.3% (HR = 1.043; p < 0.001).
    UNASSIGNED: Higher SMI increases the risk of postoperative complications, yet it significantly improves overall survival rates. Different BMI categories lack RCC prognostic significance. The increasing incidence in RCC calls for the use of CT scan to assess SMI and aid treatment planning in patients who might benefit from preoperative interventions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景本研究旨在评估改良的格拉斯哥预后评分(mGPS)在转移性结直肠癌(mCRC)患者中的预后意义。方法对在布加勒斯特埃利亚斯大学急诊医院肿瘤科接受治疗和随访的65例诊断为IV期结直肠癌的患者进行回顾性分析,罗马尼亚,从2016年1月到2024年1月。收集患者数据,包括人口统计信息,肿瘤特征,和实验室参数。根据血清白蛋白和C反应蛋白(CRP)水平计算mGPS。患者分为以下三个mGPS类别:0(正常CRP和白蛋白),1(升高的CRP或低白蛋白血症),和2(升高的CRP和低白蛋白血症)。结果在纳入的65例患者中,男性33人(50.8%),女性32人(49.2%),平均年龄63.7岁.根据MGPS,25例(38.5%)患者得分为0分,30例(46.2%)得分为1分,10例(15.4%)得分为2分。中位总生存期(OS)为53个月(95%置信区间(CI)=23.512-82.488),中位无进展生存期(PFS)为23个月(95%CI=19.244-26.756)。尽管在治疗组之间观察到中位PFS和OS的数值差异,这些差异没有统计学意义(PFS:p=0.292;OS:p=0.5).结论mGPS是mCRC的有用预后工具,提供对患者生存结果的见解。然而,我们需要更大样本量的进一步研究来验证这些发现,并阐明mGPS在指导mCRC患者临床决策中的作用.
    Background This study aims to evaluate the prognostic significance of the modified Glasgow Prognostic Score (mGPS) in patients with metastatic colorectal cancer (mCRC). Methodology A retrospective analysis was conducted among 65 patients diagnosed with stage IV colorectal cancer who received treatment and follow-up at the Oncology Department of Elias Emergency University Hospital in Bucharest, Romania, from January 2016 to January 2024. Patient data were collected, including demographic information, tumor characteristics, and laboratory parameters. The mGPS was calculated based on serum albumin and C-reactive protein (CRP) levels. Patients were stratified into the following three mGPS categories: 0 (normal CRP and albumin), 1 (elevated CRP or hypoalbuminemia), and 2 (elevated CRP and hypoalbuminemia). Results Of the 65 patients included, 33 (50.8%) were male and 32 (49.2%) were female, with a mean age of 63.7 years. According to mGPS, 25 (38.5%) patients scored 0, 30 (46.2%) scored 1, and 10 (15.4%) scored 2. The median overall survival (OS) was 53 months (95% confidence interval (CI) = 23.512-82.488), and the median progression-free survival (PFS) was 23 months (95% CI = 19.244-26.756). Although numerical differences in the median PFS and OS were observed between treatment groups, these differences were not statistically significant (PFS: p = 0.292; OS: p = 0.5). Conclusions The mGPS is a useful prognostic tool in mCRC, providing insights into patient survival outcomes. However, further studies with larger sample sizes are needed to validate these findings and clarify the role of mGPS in guiding clinical decision-making for mCRC patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    步行社区与步行频率的增加和社会凝聚力的增强密切相关。这些因素,反过来,有助于降低BMI和其他积极的健康相关结果。然而,随着中国老龄化人口的迅速增加,女性在年龄上比男性面临更多的挑战,特别是流动性挑战,因为他们往往活得更长,导致成为寡妇的可能性。然而,人们对理解这些关系之间的性别差异的关注较少。
    根据对大连市533名老年人的调查,中国,这项研究试图调查感知步行能力之间的交织关系,社会凝聚力,行走频率,BMI。采用结构方程模型(SEM)和多组分析对所提出的框架进行了测试。
    首先,结果表明,上述相互关系之间存在性别差异,最大的性别差距是社会凝聚力对BMI的影响。第二,感知步行能力仅对女性老年人的步行频率有直接影响(0.149)。第三,尽管感知步行能力和BMI之间的关系在男性和女性模型中都没有直接关系,间接联系(-0.053)代替女性老年人。此外,步行对BMI的抑制作用,这是-0.511,也适用于女性老年人。最后,就社会凝聚力的作用而言,在男性(0.142)和女性模型(0.103)中已经证实了感知步行能力对其的积极影响(男性为0.225,女性为0.325)及其对步行的促进作用。社会凝聚力对BMI(-0.083)的负面直接影响仅在男性老年人中得到证实。
    由此分析得出的见解可以帮助提出针对性别的干预措施,以建立更具包容性的步行和社会环境,以改善老年人的行动能力和身体健康。
    UNASSIGNED: Walkable neighborhoods are closely related to an increase in walking frequency and the strengthening of social cohesion. These factors, in turn, contribute to lower BMI and other positive health-related outcomes. However, with a rapid increase in aging populations in China and the fact that women are facing more challenges than men as they age, especially mobility challenges because they tend to live longer leading to probabilities to become widowed. Nevertheless, less attention has been paid to understanding the gender difference between these relationships.
    UNASSIGNED: Based on a survey of 533 older adults in Dalian, China, this study tried to investigate the intertwined relationship between perceived walkability, social cohesion, walking frequency, and BMI. A Structural Equation Model (SEM) and multiple-group analysis were applied to test the proposed framework.
    UNASSIGNED: First, results show that gender differences existed among the above interrelationships, and the most substantial gender gap was found in effects of social cohesion on BMI. Second, perceived walkability only has a direct effect (0.149) on walking frequencies for female seniors. Third, although the relationships between perceived walkability and BMI are not directly related in both male and female models, the indirect connection (-0.053) is substituted for female seniors. Besides, the inhibiting effect of walking on BMI, which is -0.511, is also valid for female seniors. Finally, in terms of the role of social cohesion, both the positive impacts of perceived walkability on it (0.225 for males and 0.325 for females) and its promoting effects on walking have been confirmed in male (0.142) and female models (0.103). The negative direct effect of social cohesion on BMI (-0.083) is only confirmed in male seniors.
    UNASSIGNED: Insights derived from this analysis can help bring forward gender-specific interventions to build a more inclusive walkable and social environment to improve the mobility and physical health of older adults.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:Dupilumab是一种用于治疗中度/重度特应性皮炎(AD)的单克隆抗体。近年来,几项研究证实了AD与超重/肥胖之间的正相关,一份报告证明了减轻体重对改善AD症状的作用。方法:在基线和48周后(T48)记录170例接受dupilumab治疗的患者的体重。临床监测主要采用湿疹面积和严重程度指数(EASI)。该研究旨在评估dupilumab治疗的临床结果与BMI之间可能的相关性。结果:虽然没有统计学意义,BMI<25的患者在任何时间点都比BMI≥25的患者有更高的EASI改善百分比,与体重正常的患者相比,在T48时未达到EASI-75的超重和肥胖患者的百分比更高(13.5%vs.5.9%)。尽管如此,在多元回归分析中,无基线特征,包括BMI,似乎增加了未达到EASI-75的风险。此外,结果显示,在任何年龄/性别组,基线和T48之间的BMI没有差异.结论:研究结果表明,当考虑EASI评分时,超重和肥胖患者对dupilumab的反应较低,但这种差异在临床上似乎并不显著。此外,dupilumab治疗似乎不会影响体重.
    Background: Dupilumab is a monoclonal antibody used for the treatment of moderate/severe atopic dermatitis (AD). In recent years, several studies have confirmed the positive association between AD and overweight/obesity, and a report demonstrated the effect of weight reduction on the improvement of AD symptoms. Methods: The weight of 170 patients under treatment with dupilumab was recorded at baseline and after 48 weeks (T48). Clinical monitoring was mainly conducted using the Eczema Area and Severity Index (EASI). The study aimed to assess a possible correlation between the clinical outcome of dupilumab therapy and BMI. Results: Although not statistically significant, patients with a BMI < 25 have a higher EASI percentage improvement than patients with a BMI ≥ 25 at any time point, and the percentage of overweight and obese patients that does not reach EASI-75 at T48 is higher compared to normal-weight patients (13.5% vs. 5.9%). Despite this, in the multivariate regression analysis, no baseline characteristic, including BMI, appears to increase the risk of not reaching EASI-75. In addition, the results show no differences in BMI between baseline and T48 in any age/sex group. Conclusions: The results suggest that overweight and obese patients have a lower response to dupilumab when considering the EASI score, but this difference does not appear to be clinically significant. Furthermore, dupilumab treatment does not seem to impact weight.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目前,全球缺乏全面的数据,国家,成人非酒精性脂肪性肝病(NAFLD)患病率的地区水平。这项横断面研究旨在确定NAFLD和非酒精性脂肪性肝炎(NASH)的患病率,利用体重指数(BMI)作为决定因素。
    基于NHANES数据库,生成S形拟合曲线以建立BMI与NAFLD/NASH风险之间的关系。利用来自NCD风险因素合作(NCD-RisC)数据库的全球和区域层面的BMI数据,从1975年到2016年,成人NAFLD/NASH的患病率估计,包括全球,区域,和国家观点。此外,预测了2017年至2030年成人NAFLD/NASH的患病率。
    2016年,NAFLD的全球患病率男性为41.12%,女性为37.32%,而NASH的全球患病率男性为15.79%,女性为16.48%.在两种性别中,NAFLD/NASH的患病率随着BMI的升高而增加。在1975年至2016年期间,成人NAFLD/NASH的全球患病率逐渐增加,这一趋势预计将在2017年至2030年之间持续。在男性中,成人NAFLD/NASH的患病率在高收入西方国家最高,虽然它在中亚最高,中东,和1995年后的北非国家。
    观察到成人NAFLD/NASH的患病率逐年增加,不同国家和地区的负担差异很大。
    UNASSIGNED: At present, there is a dearth of comprehensive data at the global, national, and regional levels regarding the adult non-alcoholic fatty liver disease (NAFLD) prevalence. This cross-sectional study aims at ascertaining the prevalence of NAFLD and non-alcoholic steatohepatitis (NASH), utilizing body mass index (BMI) as a determining factor.
    UNASSIGNED: Based on the NHANES database, sigmoidal fitting curves were generated to establish the relationship between BMI and the risk of NAFLD/NASH. Utilizing BMI data from the NCD Risk Factor Collaboration (NCD-RisC) database at both global and regional levels, the prevalence of NAFLD/NASH among adults was estimated from 1975 to 2016, encompassing global, regional, and national perspectives. Additionally, projections were made to forecast the prevalence of adult NAFLD/NASH from 2017 to 2030.
    UNASSIGNED: In 2016, the global prevalence of NAFLD was 41.12% for males and 37.32% for females, while the global prevalence of NASH was 15.79% for males and 16.48% for females. The prevalence of NAFLD/NASH increased with higher BMI in both genders. Over the period from 1975 to 2016, there has been a gradual increase in the global prevalence of NAFLD/NASH in adults, and this trend is expected to continue between 2017 and 2030. In males, the prevalence of adult NAFLD/NASH was found to be highest in High-income Western countries, while it was highest in Central Asia, Middle East, and North African countries after 1995.
    UNASSIGNED: The prevalence of adult NAFLD/NASH has been observed to increase annually, with significant variations in burden across different countries and regions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:全球肥胖率一直在增加,导致膝骨性关节炎的发病率较高,初次和翻修全膝关节置换术(TKA)激增。关于肥胖对TKA成功的影响的争论仍在继续,特别是关于在肥胖患者中使用茎状胫骨组件。这项系统评价旨在比较在接受TKA的肥胖患者中,柄胫骨组件与标准龙骨胫骨组件的有效性。假设茎成分会产生更好的临床和放射学结果.
    方法:根据系统评价和荟萃分析(PRISMA)声明指南的首选报告项目进行系统评价。包括PubMed在内的数据库,Embase,Scopus,和WebofScience从成立到2023年12月进行了搜索。资格标准基于PICO框架;参与者:肥胖患者接受TKA,干预:茎TKA,比较器:标准龙骨胫骨TKA,结果:无菌性松动,患者报告的结果措施(PROMs),和整体修订。使用纽卡斯尔-渥太华量表进行队列研究,并使用Cochrane偏见风险工具进行随机试验,进行数据提取和质量评估。
    结果:搜索产生了470项研究,10项研究(42,533膝)符合纳入标准。这些研究包括三个随机临床试验和七个回顾性队列。测量的主要结果是无菌性松动和总体翻修率,而次要结果包括PROM。结果表明混合发现,一些研究表明,在无菌性松动和机械故障的情况下,茎组件的结局有所改善,而其他人则没有显着差异。PROM在TKA后的组间没有显示出显著差异。使用建议分级,证据的确定性被评为“非常低”,评估,发展,和评价(等级)框架。
    结论:目前的文献没有提供确凿的证据支持在肥胖患者的TKA中常规使用柄状胫骨组件。使用延长茎的决定不应仅仅依赖于患者的肥胖状况。需要进一步的高质量研究来阐明茎状成分在该患者人群TKA中的作用。
    BACKGROUND: Obesity rates have been increasing globally, leading to a higher incidence of knee osteoarthritis and a surge in primary and revision total knee arthroplasty (TKA). The debate continues on the impact of obesity on TKA success, particularly regarding the use of stemmed tibial components in obese patients. This systematic review aimed to compare the effectiveness of stemmed tibial components versus standard keeled tibial components in obese patients undergoing TKA, hypothesizing that stemmed components would yield better clinical and radiological outcomes.
    METHODS: A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines. Databases including PubMed, Embase, Scopus, and Web of Science were searched from inception to December 2023. The eligibility criteria were based on the PICO framework; Participants: Patients who have obesity undergoing TKA, Intervention: stemmed TKA, Comparator: standard keeled tibial TKA, Outcome: aseptic loosening, Patient-Reported Outcome Measures (PROMs), and overall revision. Data extraction and quality assessment were performed using the Newcastle-Ottawa Scale for cohort studies and the Cochrane risk-of-bias tool for randomized trials.
    RESULTS: The search yielded 470 studies, with 10 studies (42,533 knees) meeting the inclusion criteria. These studies included three randomized clinical trials and seven retrospective cohorts. The primary outcomes measured were aseptic loosening and overall revision rates, while secondary outcomes included PROMs. Results indicated mixed findings, with some studies suggesting improved outcomes with stemmed components in cases of aseptic loosening and mechanical failure, while others showed no significant difference. The PROMs did not show a significant difference between groups post-TKA. The certainty of the evidence was graded as \"very low\" using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework.
    CONCLUSIONS: Current literature does not provide conclusive evidence to support the routine use of stemmed tibial components in TKA for obese patients. The decision to use stem extensions should not solely rely on the patient\'s obesity status. Further high-quality studies are needed to clarify the role of stemmed components in TKA for this patient population.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    多发性硬化症(MS)患者有许多潜在因素(疾病持续时间,痉挛,固定化,或糖皮质激素的使用)可能会恶化其营养状况并影响疾病的进展和预后。身体质量指数(BMI),最广泛使用的营养状况评估工具,具有重要的局限性,因为它不提供有关身体成分的任何数据。
    本研究旨在通过使用生物电阻抗分析(BIA)评估体重指数(BMI)和身体成分的营养状况评估与体重不足/脂肪不足诊断的一致性之间的相互关系。正常体重/健康,超重/超重,和肥胖/肥胖MS患者。
    在176例MS患者中评估了人体测量[BMI和腰围与身高比(WHtR)]和身体成分(BIA)数据。患者分为四个营养状况亚组(体重不足,正常体重,超重,根据BMI肥胖,脂肪不足,健康,脂肪过多,根据BIA的脂肪质量%和肥胖)。扩展的残疾状态量表评分中位数为4.5。然后根据EDSS评分将患者分为轻度(EDSS1.0-4.0)或中度(EDSS4.5-6.5)残疾亚组。
    基于BIA评估,基于BMI[n=50(28.41%)与超重的患病率明显高于超重的患病率n=38(21.59%);p<0.05]。然而,无论诊断方式如何,肥胖的患病率都没有显着差异,并且在使用BIA评估时也没有显着降低[n=26(14.77%)与n=30(17.05%),分别]。对于所有MS患者以及轻度和中度亚组,使用BMI和BIA进行诊断的总体兼容率(CR)分别为75.6%,77.0%和70.1%。分别。在超重组中观察到最低CR。在所有亚组中,肥胖显著低估了BMI。在中度MS亚组中,BMI将MS患者显著过度分类为具有正常体重(p<0.05)。腹部肥胖的分层(WHtR>0.5)表明,BMI明显低估了超重和肥胖的MS患病率。肥胖和肥胖的病人,使用BIA评估(60.5vs.67%;p<0.05)。临床状态(EDSS和ΔEDSS)与使用BIA评估的FAT%分类的营养状况比使用BMI截止点更密切相关。然而,这种关系没有统计学意义.
    使用BMI截止点来评估MS患者的营养状况与过度脂肪量的明显低估有关。在MS患者中,基于BIA的FAT%与腹部肥胖和残疾状态的关系比与BMI的关系更好。假阴性诊断率最高的是基于MS和中度残疾患者的BMI。使用BIA进行脂肪评估似乎是对患者组进行适当营养状况评估的有用方法。
    UNASSIGNED: Patients with multiple sclerosis (MS) have many potential factors (disease duration, spasticity, immobilization, or glucocorticoid use) that can deteriorate their nutritional status and impact both the progression and prognosis of the disease. Body mass index (BMI), the most widely used nutritional status assessment tool, has important limitations because it does not provide any data on body composition.
    UNASSIGNED: This study aimed to assess the interrelationship between nutritional status assessment by both body mass index (BMI) and body composition using bioelectrical impedance analysis (BIA) and the consistency of diagnosis for underweight/underfat, normal weight/healthy, overweight/overfat, and obesity/obese MS patients.
    UNASSIGNED: Anthropometric [BMI and waist-to-height ratio (WHtR)] and body composition (BIA) data were evaluated in 176 patients with MS. Patients were categorized into four nutritional status subgroups (underweight, normal weight, overweight, obese according to BMI, and underfat, healthy, overfat, and obese according to fat mass% by BIA). The median Expanded Disability Status Scale score was 4.5. Patients were then divided according to EDSS score as mild (EDSS 1.0-4.0) or moderate (EDSS 4.5-6.5) disability subgroups.
    UNASSIGNED: Based on BIA assessment, there was a significantly higher prevalence of overfat than of overweight based on BMI [n = 50 (28.41%) vs. n = 38 (21.59%); p < 0.05]. However, the prevalence of obesity did not differ significantly regardless of the mode of diagnosis and was not significantly lower when assessed using BIA [n = 26 (14.77%) vs. n = 30 (17.05%), respectively]. The overall compatibility rates (CR) of diagnoses made using both BMI and BIA were 75.6, 77.0, and 70.1% for all patients with MS and the mild and moderate subgroups, respectively. The lowest CR was observed in the overweight group. Adiposity significantly underestimated BMI in all subgroups. In the moderate MS subgroup, BMI significantly overcategorized patients with MS as having a normal weight (p < 0.05). Stratification for abdominal obesity (WHtR > 0.5) showed that BMI significantly underestimated the prevalence of MS in overweight and obese vs. overfat and obese patients, as assessed using BIA (60.5 vs. 67%; p < 0.05). Clinical status (EDSS and ΔEDSS) was more closely related to the nutritional status categorized by FAT% assessed using BIA than using BMI cutoff points. However, the relationship was not statistically significant.
    UNASSIGNED: Using the BMI cutoff point for nutritional status assessment in patients with MS is associated with a significant underestimation of excess fat mass. BIA-based FAT% based on BIA have a better relationship with abdominal obesity and disability status than with BMI in patients with MS. The highest rate of false-negative diagnoses was based on the BMI in patients with MS and moderate disability. Adiposity assessment using BIA appears to be a useful method for proper nutritional status assessment in the patients group.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    关于肥胖对腹膜后腹腔镜肾上腺切除术(RLA)后手术结果的影响的证据不一致。本研究旨在探讨肥胖对RLA患者手术结局的影响。强调手术时间,引流管拔除时间,术后住院时间和围手术期并发症。
    在这次回顾中,单中心,观察性研究,纳入2012年1月至2021年12月所有因肾上腺疾病而出现的单侧RLA的连续病例.根据28kg/m2的体重指数(BMI)将患者分为两组。为了减轻选择偏差,进行倾向评分匹配(PSM),使用逻辑回归计算平衡基线特征的倾向得分。进行了多变量逻辑回归分析,以评估肥胖如何影响手术时间和术中失血量。BMI与手术结果之间的线性相关,包括手术时间延长和术中失血量增加,还使用受限三次样条(RCS)分析进行了检查。
    共纳入569例接受RLA的患者。PSM之后,122名患者被分配到每组。肥胖组和非肥胖组手术时间差异有统计学意义(97.5vs.115分钟,P<0.001)。两组住院时间无统计学差异(6.7vs.6.8天,P=0.58),引流管移除时间(3.0vs.3.0天,P=0.19),也没有术后并发症(9.0%vs.12.3%,P=0.41)。此外,单因素Logistic回归分析显示,接受RLA的肥胖患者与手术时间延长和术中失血量增加有关.在调整了潜在的混杂因素后,肥胖组手术时间延长的风险增加了67%,术中失血量增加了69%.RCS分析显示,BMI与手术时间(P表示非线性=0.47)和术中出血量(P表示线性=0.89)呈线性关系。
    在接受RLA的患者中,肥胖对手术结果有显著影响,特别是关于手术时间和术中失血,如多变量逻辑回归分析和PSM所示,以平衡基线特征。
    UNASSIGNED: There is inconsistent evidence regarding obesity\'s effect on surgical outcomes following retroperitoneal laparoscopic adrenalectomy (RLA). This study aimed to investigate the influence of obesity on surgical outcomes in patients undergoing RLA, with an emphasis on operative time, drainage tube removal time, postoperative hospital stays and perioperative complications.
    UNASSIGNED: In this retrospective, single-center, observational study, all consecutive cases of unilateral RLA for adrenal disease from January 2012 to December 2021 were incorporated. The patients were divided into two groups based on their body mass index (BMI) of 28 kg/m2. To mitigate selection bias, propensity score matching (PSM) was conducted, using logistic regression to calculate propensity scores for balancing baseline characteristics. A multivariate logistic regression analysis was performed to assess how obesity affects operative time and intraoperative blood loss as well. The linear correlation between BMI and surgical outcomes, including prolonged operative time and increased intraoperative blood loss, was also examined using restricted cubic spline (RCS) analysis.
    UNASSIGNED: A total of 569 patients who underwent RLA were included. After PSM, 122 patients were apportioned to each group. Statistically significant differences were observed between the obese and non-obese group in operative time (97.5 vs. 115 min, P<0.001). There were no statistically significant differences between the two groups regarding hospital stay (6.7 vs. 6.8 days, P=0.58), drainage tube removal time (3.0 vs. 3.0 days, P=0.19), nor postoperative complications (9.0% vs. 12.3%, P=0.41). Furthermore, univariate logistic regression analysis revealed that, obese patients undergoing RLA were linked to prolonged operative time and increased intraoperative blood loss. After adjusting for potential confounders, the obese group showed a 67% increased risk of prolonged operative time and a 69% increased intraoperative blood loss. The RCS analysis revealed that BMI had a linear relationship with operative time (P for nonlinearity =0.47) and blood loss during surgery (P for linearity =0.89).
    UNASSIGNED: In patients undergoing RLA, obesity exerts a significant influence on surgical outcomes, particularly with regard to operative time and intraoperative blood loss, as shown in multivariable logistic regression analysis and PSM to balance baseline characteristics.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:这项研究调查了体重指数(BMI)与癫痫发作年龄的关系,与颞叶脑囊肿(TEs)相关的癫痫患者。
    方法:使用关键词“颞叶脑瘤”和“癫痫”进行了全面的PubMed文献综述,以确定用于分析的文章。纳入标准包括报告TE相关癫痫患者和记录BMI的所有证据水平。进行Logistic回归分析,以检查BMI对25岁后癫痫发作的预测作用。Spearman相关性评估BMI与癫痫发作之间的关系。最后,BMI与手术后结局之间的关系,我们探讨了比较有利的结果(EngelI类和II类)和较差的结果(EngellIII类和IV类)之间的区别.
    结果:在最初确定的88篇文章中,9个被包括在分析中,涉及127例TE相关癫痫患者,报告BMI。癫痫发作的平均年龄为24.9岁(SD=14.8岁),平均BMI为28.0kg/m2(SD=7.4kg/m2)。BMI与癫痫发病年龄呈显著正相关(rho=0.448,p<0.001)。女性患者的BMI高于男性患者(分别为30.1kg/m2,SD=8.7kg/m2和26.5kg/m2,SD=5.3kg/m2,p=0.008)。然而,男性和女性患者的癫痫发作无显著差异(p=0.26).双变量logistic回归分析显示,BMI升高的患者在25岁以后更容易发生癫痫,根据混杂性别调整(OR=1.133,95%-CI[1.060,1.211],p<0.001)。最后,一个潜在的趋势表明,术后结局较好的患者的平均BMI高于术后结局较差的患者(分别为27.3kg/m2,SD=7.7kg/m2和24.8kg/m2,SD=2.2kg/m2,p=0.076)。
    OBJECTIVE: This study investigates the association of Body Mass Index (BMI) and age of epilepsy onset, in patients with epilepsy associated with temporal encephaloceles (TEs).
    METHODS: A comprehensive PubMed literature review was conducted using the keywords \"temporal encephaloceles\" and \"epilepsy\" for identifying articles for the analysis. Inclusion criteria encompassed all evidence levels reporting patients with TE-related epilepsy and documented BMI. Logistic regression analyses were performed to examine the effect of BMI on predicting epilepsy onset after the 25th year of age. Spearman\'s correlation assessed the relationship between BMI with epilepsy onset. Finally, the association between BMI and postsurgical outcomes, distinguishing between more favourable outcomes (Engel Class I and II) and less favourable outcomes (Engell Class III and IV) was explored.
    RESULTS: Of the initially identified 88 articles, nine were included in the analysis, involving 127 patients with TE-related epilepsy and reported BMI. The mean age of epilepsy onset was 24.9 years (SD = 14.8 years), with a mean BMI of 28.0 kg/m2 (SD = 7.4 kg/m2). A significant positive correlation was observed between BMI and age of epilepsy onset (rho = 0.448, p < 0.001). Female patients had higher BMI compared to male patients (30.1 kg/m2, SD = 8.7 kg/m2 and 26.5 kg/m2, SD = 5.3 kg/m2 respectively, p = 0.008). However, the epilepsy onset did not differ significantly between male and female patients (p = 0.26). The bivariate logistic regression showed that patients with increased BMI were more likely to have an epilepsy onset after the 25th year of age, adjusted for the confounder sex (OR = 1.133, 95%-CI [1.060, 1.211], p < 0.001). Finally, a potential trend indicated a higher average BMI among patients with more favourable postsurgical outcomes than less favourable postsurgical outcomes (27.3 kg/m2, SD = 7.7 kg/m2 and 24.8 kg/m2, SD = 2.2 kg/m2 respectively, p = 0.076).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    到现在为止,COVID-19仍然是一个尚未解决的大流行,氧化还原稳态的损害决定了临床结局的严重程度。在这里,我们检查了3月1日至4月1日期间住院的440名COVID-19患者的初始UCLA队列,2020年,代表着疫情的第一波。平均年龄为58.88±21.12,其中男性明显多于女性(55.5%vs.44.5%),在50-69岁年龄段最明显。50-69岁(33.6%)和≥70岁(34.8%)的年龄组占主导地位。种族构成与人口普查数据基本一致,西班牙裔和亚洲人的代表性略有不足,和白种人的过度代表。吸烟是一个重要因素(28.8%与洛杉矶人口中的11.0%),肥胖(BMI≥30)(37.4%vs.洛杉矶人口中的27.7%)。患有肥胖症或BMI<18.5的患者进入ICU的比率明显更高。74.5%的患者有糖尿病等合并症,慢性肾病,慢性肺病,充血性心力衰竭和外周血管疾病。D-二聚体水平急剧上调(1159.5ng/mL),指示高凝状态。LDH上调(328IU/L)表示显著的组织损伤。扭曲的氧化还原平衡是与这些风险因素和临床标志物相关的常见特征。四分之一的病人接受了抗病毒治疗,其中雷德西韦处方最多(23.6%)。大多数接受抗血栓治疗(75%),和抗生素。一被录取,67例患者接受了插管或CPR;177例患者最终接受了重症监护(40.2%)。当290人活着出院时,仍有10人住院,73人被转移,36例死亡,3例姑息出院。总之,我们的数据充分描述了加州人群COVID-19在大流行爆发阶段的特征,表明人口统计,生物物理字符,合并症和分子病理参数对大流行的演变有重大影响。这些为有效管理COVID-19提供了关键见解,并在未来摆脱另一种病原体。
    To this date, COVID-19 remains an unresolved pandemic, and the impairment of redox homeostasis dictates the severity of clinical outcomes. Here we examined initial UCLA cohort of 440 COVID-19 patients hospitalized between March 1st and April 1st, 2020, representing the first wave of the pandemic. The mean age was 58.88 ± 21.12, among which males were significantly more than females (55.5 % vs. 44.5 %), most distinctively in age group of 50-69. The age groups of 50-69 (33.6 %) and ≥70 (34.8 %) dominated. The racial composition was in general agreement with Census data with slight under-representation of Hispanics and Asians, and over-representation of Caucasians. Smoking was a significant factor (28.8 % vs. 11.0 % in LA population), likewise for obesity (BMI ≥30) (37.4 % vs. 27.7 % in LA population). Patients suffering from obesity or BMI<18.5 checked into ICU at a significantly higher rate. A 74.5 % of the patients had comorbidities including diabetes, chronic kidney disease, chronic pulmonary disease, congestive heart failure and peripheral vascular disease. The levels of d-dimer were drastically upregulated (1159.5 ng/mL), indicating hypercoagulative state. Upregulated LDH (328 IU/L) indicated significant tissue damages. A distorted redox hemeostasis is a common trait associated with these risk factors and clinical markers. A quarter of the patients received antivirals, among which Remdesivir most prescribed (23.6 %). Majority received antithrombotics (75 %), and antibiotics. Upon admission, 67 patients were intubated or received CPR; 177 patients eventually received intensive care (40.2 %). While 290 were discharged alive, 10 remained hospitalized, 73 were transferred, and 36 died with 3 palliatively discharged. In summary, our data fully characterized a Californian cohort of COVID-19 at the breaking phase of the pandemic, indicating that population demographics, biophysical characters, comorbidities and molecular pathological parameters have significant impacts on the evolvement of a pandemic. These provide critical insights into effective management of COVID-19, and future break from another pathogen.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号